A5091175271- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Immune cells in cancer
- Immunotherapy and Immune Responses
- Colorectal Cancer Treatments and Studies
- Ferroptosis and cancer prognosis
- Cancer Genomics and Diagnostics
- Radiomics and Machine Learning in Medical Imaging
- Single-cell and spatial transcriptomics
- Monoclonal and Polyclonal Antibodies Research
- Cancer Diagnosis and Treatment
- vaccines and immunoinformatics approaches
- Radiopharmaceutical Chemistry and Applications
- Glycosylation and Glycoproteins Research
- Lung Cancer Research Studies
- Neuroendocrine Tumor Research Advances
University of California, Los Angeles
2018-2022
UCLA Health
2018-2020
The US Oncology Network
2019
Several biomarkers have been individually associated with response to PD-1 blockade, including PD-L1 and tumor mutational burden (TMB) in non-small cell lung cancer (NSCLC), CD8 cells melanoma. We sought examine the relationship between these distinct variables blockade long-term benefit.
Abstract Purpose: Immune checkpoint inhibitors (ICI) have revolutionized the treatment of non–small cell lung cancer (NSCLC), but predictive biomarkers their efficacy are imperfect. The primary objective is to evaluate circulating immune predictors pembrolizumab in patients with advanced NSCLC. Experimental Design: We used high-dimensional mass cytometry (CyTOF) baseline blood samples NSCLC treated pembrolizumab. CyTOF data were analyzed by machine-learning algorithms (Citrus, tSNE) and...
9014 Background: Despite the significant antitumor activity of pembrolizumab in non-small cell lung cancer (NSCLC), clinical benefit has been less frequently observed patients whose tumors harbor epidermal growth factor receptor (EGFR) mutations compared to EGFR wild-type patients. Our single center experience on KEYNOTE-001 trial suggested that pembrolizumab-treated EGFR-mutant patients, who were tyrosine kinase inhibitor (TKI) naïve, had superior outcomes those previously treated with a...
<div>AbstractPurpose:<p>Immune checkpoint inhibitors (ICI) have revolutionized the treatment of non–small cell lung cancer (NSCLC), but predictive biomarkers their efficacy are imperfect. The primary objective is to evaluate circulating immune predictors pembrolizumab in patients with advanced NSCLC.</p> Experimental Design:<p>We used high-dimensional mass cytometry (CyTOF) baseline blood samples NSCLC treated pembrolizumab. CyTOF data were analyzed by...
<p>Supplementary Figure 1: Graphical Abstract Supplementary 2: Overall Survival in NSCLC patients treated with pembrolizumab KEYNOTE-001 according to EGFR mutation 3: Recursive partitioning identified classical monocytes and NK as the main immune populations whose frequency splits into distinct patterns of overall survival 4: Classical monocytes, cells ICOS+ CD4+ T are associated improved efficacy advanced patients. 5: Gating strategy 3 efficacy. 6: Comparison side by Maxstat cut-offs...
<p>Supplementary Figure 1: Graphical Abstract Supplementary 2: Overall Survival in NSCLC patients treated with pembrolizumab KEYNOTE-001 according to EGFR mutation 3: Recursive partitioning identified classical monocytes and NK as the main immune populations whose frequency splits into distinct patterns of overall survival 4: Classical monocytes, cells ICOS+ CD4+ T are associated improved efficacy advanced patients. 5: Gating strategy 3 efficacy. 6: Comparison side by Maxstat cut-offs...
<div>AbstractPurpose:<p>Several biomarkers have been individually associated with response to PD-1 blockade, including PD-L1 and tumor mutational burden (TMB) in non–small cell lung cancer (NSCLC), CD8 cells melanoma. We sought examine the relationship between these distinct variables blockade long-term benefit.</p>Experimental Design:<p>We assessed association baseline characteristics (TMB, PD-L1, CD4, CD8) clinical features outcome 38 patients advanced NSCLC treated...
<div>AbstractPurpose:<p>Immune checkpoint inhibitors (ICI) have revolutionized the treatment of non–small cell lung cancer (NSCLC), but predictive biomarkers their efficacy are imperfect. The primary objective is to evaluate circulating immune predictors pembrolizumab in patients with advanced NSCLC.</p> Experimental Design:<p>We used high-dimensional mass cytometry (CyTOF) baseline blood samples NSCLC treated pembrolizumab. CyTOF data were analyzed by...
<div>AbstractPurpose:<p>Several biomarkers have been individually associated with response to PD-1 blockade, including PD-L1 and tumor mutational burden (TMB) in non–small cell lung cancer (NSCLC), CD8 cells melanoma. We sought examine the relationship between these distinct variables blockade long-term benefit.</p>Experimental Design:<p>We assessed association baseline characteristics (TMB, PD-L1, CD4, CD8) clinical features outcome 38 patients advanced NSCLC treated...
<p>Supplementary Figure Legend</p>
<p>Supplemental Figure 1. Schematic presentation of the analyzed parameters in correlative cohort per progression survival (PFS). TMB: total mutational burden. PR: partial response. SD: stable disease. PD: progressive â-³: mutation. Supplemental 2. Progression Free Survival (PFS) and subgroup analysis (N=38) by Log-rank (Mantel-Cox) test. PFS By PD-L1 categories ( 0-49% n=23 vs 50-100% n=9, p<0.001) TMB percentile (<25th n=6 25-50th n=7 50-75th >75th n=6, p=0.142) CD8 (0-5%...
<p>Supplementary Figure Legend</p>
<p>Supplemental Figure 1. Schematic presentation of the analyzed parameters in correlative cohort per progression survival (PFS). TMB: total mutational burden. PR: partial response. SD: stable disease. PD: progressive â-³: mutation. Supplemental 2. Progression Free Survival (PFS) and subgroup analysis (N=38) by Log-rank (Mantel-Cox) test. PFS By PD-L1 categories ( 0-49% n=23 vs 50-100% n=9, p<0.001) TMB percentile (<25th n=6 25-50th n=7 50-75th >75th n=6, p=0.142) CD8 (0-5%...
3026 Background: In melanoma (mel) patients (pts) treated with immune checkpoint inhibitors, presence of HLA class I (HLA-1) B44 supertype (B44+) correlated survival (Chowell, Science). preferentially binds negatively charged (neg) peptides and those glutamic acid (E) at the anchor position. Positively (pos) impede binding. mel, benefit was driven by glycine (G) > E changes. We evaluated predictive role HLA-I supertypes in NSCLC as neoepitopes are likely different tranversions (Tv)...
2635 Background: Human leukocyte antigen (HLA) binding relies on energy from the interaction of B-pocket residues with anchor amino acids (AA). Among HLA class I supertypes, only HLA-B has distinct electrostatic specificities, and 7 B08, B27, B44 feature pockets preferences for charged AAs (Lund Immunogen). Whether interactions in HLA-neoepitope would identify superior neoantigens associate survival NSCLC patients treated immunotherapy was unknown. Methods: Forty advanced single agent...
3083 Background: Recent evidence suggests efficacy of immune checkpoint blockade may be influenced by human leukocyte antigen (HLA)-B. HLA-B27 supertype has an electronegative binding pocket which favorably binds and displays neoepitopes harboring positively charged amino acids (AAs). Based on surveillance, we postulate that B27 tumors have favorable should face negative selective pressure, with develop could more likely to upregulate escape mechanisms. Here evaluate the relationship between...